The role of erythropoietin preparations in the treatment of anemia in oncologic patients
- Authors: Abramov M.E1, Chikhareva Y.E1, Manukyan M.S.1, Prokofiev E.A1, Vyshinskaya G.V1
-
Affiliations:
- N.N. Blokhin Scientific Research Center of Oncology
- Issue: Vol 26, No 12 (2019)
- Pages: 80-85
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312347
- DOI: https://doi.org/10.18565/pharmateca.2019.12.80-84
- ID: 312347
Cite item
Open Access
Access granted
Abstract
Anemia is one of the most common conditions in oncologic patients. Most often, it is observed in patients with lung cancer, breast cancer, and oncogynecological patients. The clinical significance of anemia is associated with a negative impact on the quality of life, a decrease in exercise tolerance, the development of weakness and worsening treatment results. An effective and safe method for the correction of anemia is the use of erythropoietin preparations, which avoids frequent transfusions of red blood cells and reduces the risk of posttransfusion complications. Also, these drugs have neuroprotective, cardioprotective effects and increase the antioxidant activity of cells. This article analyzes foreign and domestic studies on the efficacy and safety of the use of erythropoietin preparations, indications and contraindications for their use, as well as criteria for correcting dosage regimens and drug withdrawal.
Keywords
Full Text
About the authors
M. E Abramov
N.N. Blokhin Scientific Research Center of Oncology
Email: mikhailabramov@newmail.ru
PhD 23, Kashirskoye Highway, Moscow 115478, Russian Federation
Y. E Chikhareva
N.N. Blokhin Scientific Research Center of OncologyMoscow, Russia
M. Sh Manukyan
N.N. Blokhin Scientific Research Center of OncologyMoscow, Russia
E. A Prokofiev
N.N. Blokhin Scientific Research Center of OncologyMoscow, Russia
G. V Vyshinskaya
N.N. Blokhin Scientific Research Center of OncologyMoscow, Russia
References
- Романенко Н.А. Патогенез и терапия анемии препаратами рекомбинантного эритропоэтина у онкогематологических больных (обзор современной литературы). Онкогематология. 2012;3:20-9
- Лоскутов О.А. Опасности и осложнения при проведении гемотрансфузий. Актуальи проблеми сучасноi медицини: В'сник укра1нсько1 медичноi стоматолопчноi академн. 2015;3-1(51)
- Yang W.S., Chang J.W., Han N.J., Park S.K. Darbepoetin alfa suppresses tumor necrosis factor-a- induced endothelin-1 production through antioxidant action in human aortic endothelial cells: role of sialic acid residues. Free Radic Biol Med. 2011;50(10):1242-51. Doi: 10.1016/]. freeradbiomed.2011.02.005.
- Меркулов В.А., Солдатов А.А., Авдеева Ж.И. и др. Препараты рекомбинантных эритропоэтинов и их характеристика. БИОпрепараты. Профилактика, диагностика, лечение. 2013;3(47):4-11
- Шило В.Ю. Новый эритропоэз-стимулирующий препарат Аранесп (дарбэпоэтин альфа) в коррекции анемии почечного генеза. Нефрология и диализ. 2007;9(3):216
- Mikhail A., Brown C., Williams J.A., et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC. Nephrol. 2017;18(1):345. doi: 10.1186/s12882-017-0688-1.
- Loughnan A., Ali G.R., Abeygunasekara S.C.Comparison of the therapeutic efficacy of epoetin beta and epoetin alfa in maintenance phase hemodialysis patients. Ren Fail. 2011;33(3):373-75. doi: 10.3109/0886022X.2011.559675.
- Rodriguez Garzotto A., Heine O., Turner M., et al. Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience. J Blood Med. 2014;5:43-8. doi: 10.2147/JBM. S57887.
- Tonia T, Mettler A., Robert N., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407. doi: 10.1002/14651858.CD003407.pub5.
- Leyland-Jones B., Bondarenko I., Litvin I., et al. A Randomized, Open-Label, Multicenter, Phase Ill Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy. J Clin Oncol. 2016. doi: 10.1200/JCO.2015.63.5649.
- Moebus V, Jackisch C., Schneeweiss A., et al. Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst. 2013;105(14):1018-26. doi: 10.1093/jnci/ djt145.
- Engert A, Josting A., Haverkamp H., et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol. 2010;28(13):2239-45. Doi: 10.1200/ JCO.2009.25.1835.
- Glaspy J., Crawford J., Vansteenkiste J., et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010;102(2):301-
- doi: 10.1038/sj.bjc.6605498.
- Auerbach M, Silberstein FIT., Webb R.T., et al. Darbepoetin alfa 300 or 500 mg once every 3 weeks with or without intravenous iron in patients with chemotherapyinduced anemia. Am J Hematol. 2010;85:655-63. doi: 10.1002/ajh.21779.
- Henry D.H., Dahl N.V., Auerbach M., et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007;12(2):231-42. doi: 10.1634/theoncologist.12-2-231.
- Albrand H., Luporsi E., Michallet M., Soubeyran F Abstract F1-10-02: Usage of epoetin alfa biosimilars in the management of chemotherapy-induced anemia in patients with breast cancer: A subanalysis of the ORHEO study. Cancer Res. 2016;76(Suppl. 4). doi: 10.1158/1538-7445. SABCS15-F1-10-02.
- NCCN Guidelines Version 2.2019 Management of Cancer- and Chemotherapy-induced Anemia. 2019.
- Лыков А.П., Суровцева М.А., Повещенко О.В. и др. Антиоксидантный эффект эритропоэтина. Современные проблемы науки и образования. 2018;6:18.
- Todaro M., Turdo A., Bartucci M., et al. Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res. 2013;73:6393-400. doi: 10.1158/0008-5472.CAN-13-0248
Supplementary files
